Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals only.
      BOTOX® (botulinum toxin type A) Prescribing Information and adverse event reporting information can be found below.

      NDO D 2
      NDO M 2

      UK-BUO-250027. DOP: May 2025.

      Treatment options for neurogenic detrusor overactivity (NDO)

      The goals of NDO treatment are to protect the upper urinary tract, achieve (or maintain) urinary continence, improve patients’ quality of life and restore lower urinary tract function.6,7 Additional considerations are the potential for future complications, the patient’s condition, and the ease and cost-effectiveness of treatment.6

      Treatment options for NDO include:5,7

       Lifestyle advice/behavioural approaches

       Assisted emptying

       Containment

       Pharmacotherapy

       Botulinum toxin type A

       Neurostimulation

       Surgery

      Lifestyle/behavioural interventions for NDO include the use of regular voiding schedules and pelvic floor muscle exercises.6

      Lifestyle/behavioural interventions for NDO include the use of regular voiding schedules and pelvic floor muscle exercises.6

      Lifestyle/behavioural interventions for NDO include the use of regular voiding schedules and pelvic floor muscle exercises.6

      Lifestyle/behavioural interventions for NDO include the use of regular voiding schedules and pelvic floor muscle exercises.6

      Lifestyle/behavioural interventions for NDO include the use of regular voiding schedules and pelvic floor muscle exercises.6

      Lifestyle/behavioural interventions for NDO include the use of regular voiding schedules and pelvic floor muscle exercises.6

      Lifestyle/behavioural interventions for NDO include the use of regular voiding schedules and pelvic floor muscle exercises.6

      The goals of NDO treatment are to protect the upper urinary tract, achieve (or maintain) urinary continence, improve patients' quality of life and restore lower urinary tract function6,7

      NDO: neurogenic detrusor overactivity.

      WHY CONSIDER BOTOX®

       

      © NICE [2012] Urinary incontinence in neurological disease. Available from nice.org.uk. All rights reserved. Subject to Notice of rights

      NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Stöhrer M, Blok B et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56:81–8
      7. Blok B, et al. EAU Guidelines on Neuro-Urology. 2025. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Neuro-Urology-2025.pdf. Accessed June 2025.
      8. Chapple C R, Yamanishi T and Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology. 2002;60(5):82-88
      9. Chapple C R, Khullar V et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543–62
      10. Andersson KE et al. Pharmacological treatment of urinary incontinence. 3rd International Consultation on Incontinence. 2004
      11. Wagg A, Compion G et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110:1767–74
      12. Gray S L, Anderson M L et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401–7
      13. Guiho T, Azevedo-Coste C et al. Sacral Anterior Root Stimulation and Visceral Function Outcomes in Spinal Cord Injury–A Systematic Review of the Literature Over Four Decades. World Neurosurg. 2022;157:218-232.e14
      14. Oerlemans DJAJ, van Kerrebrock PEV. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neururol Urodyn. 2008;27:28–33
      15. Sanford M T and Suskind A M. Neuromodulation in neurogenic bladder. Transl Abdrol Urol. 2016;5:117–126 
      16. Abrams P et al. Incontinence: 6th Edition 2017;50
      17. National Institute for Health and Care Excellence (NICE). CG148: Urinary incontinence in neurological disease. Available at: https://www.nice.org.uk/guidance/cg148. Accessed June 2025.
      18. de Jong TPVM, Chrzan R et al. Treatment of the neurogenic bladder in spina bifida. Pediatr Nephrol. 2008;23:889–9

       

      © NICE [2012] Urinary incontinence in neurological disease. Available from nice.org.uk. All rights reserved. Subject to Notice of rights

      NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Stöhrer M, Blok B et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56:81–8
      7. Blok B, et al. EAU Guidelines on Neuro-Urology. 2025. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Neuro-Urology-2025.pdf. Accessed June 2025.
      8. Chapple C R, Yamanishi T and Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology. 2002;60(5):82-88
      9. Chapple C R, Khullar V et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543–62
      10. Andersson KE et al. Pharmacological treatment of urinary incontinence. 3rd International Consultation on Incontinence. 2004
      11. Wagg A, Compion G et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110:1767–74
      12. Gray S L, Anderson M L et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401–7
      13. Guiho T, Azevedo-Coste C et al. Sacral Anterior Root Stimulation and Visceral Function Outcomes in Spinal Cord Injury–A Systematic Review of the Literature Over Four Decades. World Neurosurg. 2022;157:218-232.e14
      14. Oerlemans DJAJ, van Kerrebrock PEV. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neururol Urodyn. 2008;27:28–33
      15. Sanford M T and Suskind A M. Neuromodulation in neurogenic bladder. Transl Abdrol Urol. 2016;5:117–126 
      16. Abrams P et al. Incontinence: 6th Edition 2017;50
      17. National Institute for Health and Care Excellence (NICE). CG148: Urinary incontinence in neurological disease. Available at: https://www.nice.org.uk/guidance/cg148. Accessed June 2025.
      18. de Jong TPVM, Chrzan R et al. Treatment of the neurogenic bladder in spina bifida. Pediatr Nephrol. 2008;23:889–9

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here

      BOTOX® PRESCRIBING INFORMATION

      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: June 2025. UK-BUO-250052.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-250217. Date of preparation June 2025. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.